Next Article in Journal
Excessive Fructose Intake Impairs Baroreflex Sensitivity and Led to Elevated Blood Pressure in Rats
Previous Article in Journal
Effect of High-Fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function
Open AccessFeature PaperArticle

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study

1
Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, 90100 Palermo, Italy
2
Periodontology Department, School of Dentistry, University of Granada, 18071 Granada, Spain
3
Department of Drug Science, Biochemistry Section, University of Catania, 95125 Catania, Italy
4
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, 90100 Palermo, Italy
5
Department of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196, USA
6
Department of Preventive Cardiology, CGH Medical Center, Sterling, IL 61081, USA
7
Department of Hypertension, Medical University of Lodz, 90137 Lodz, Poland
8
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to the work.
Nutrients 2019, 11(11), 2580; https://doi.org/10.3390/nu11112580
Received: 18 September 2019 / Revised: 14 October 2019 / Accepted: 22 October 2019 / Published: 25 October 2019
The objective was to evaluate the effects of 6 months of supplementation with Altilix®, containing chlorogenic acid and its derivatives, and luteolin and its derivatives, on cardiovascular risk and hepatic markers in subjects with metabolic syndrome (MetS). A randomized, double-blind, placebo-controlled study was performed in 100 subjects with MetS with a follow-up period of 6 months; 50 subjects were randomized to Altilix® (26 men and 24 women, mean age 63 ± 8 years) and the other 50 to placebo (28 men and 22 women, mean age 63 ± 11 years). Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up. Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively. The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD. After 6 months of Altilix® supplementation, we found a significant improvement vs. placebo in most of the evaluated parameters, including body weight (−2.40% (95% CI −3.79, −1.01); p < 0.001), waist circumference (−2.76% (95% CI −4.55, −0.96); p = 0.003), HbA1c (−0.95% (95% CI −1.22, −0.67); p < 0.001), plasma lipids, FLI (−21.83% (95% CI −27.39, −16.27); p < 0.001), hepatic transaminases, flow-mediated dilation (10.56% (95% CI 5.00, 16.12); p < 0.001), and carotid intima-media thickness (−39.48% (95% CI −47.98, −30.97); p < 0.001). Further, the improvement in cardiometabolic variables was independent of the degree of hepatic steatosis. Altilix® supplementation improved hepatic and cardio-metabolic parameters in MetS subjects. Altilix® supplementation was a beneficial approach in the management of hepatic and cardiometabolic alterations in MetS subjects. View Full-Text
Keywords: cardiovascular diseases; metabolic syndrome; non-alcoholic fatty liver disease; diabetes mellitus; type 2; cynara; dietary supplements cardiovascular diseases; metabolic syndrome; non-alcoholic fatty liver disease; diabetes mellitus; type 2; cynara; dietary supplements
Show Figures

Figure 1

MDPI and ACS Style

Castellino, G.; Nikolic, D.; Magán-Fernández, A.; Malfa, G.A.; Chianetta, R.; Patti, A.M.; Amato, A.; Montalto, G.; Toth, P.P.; Banach, M.; Cicero, A.F.G.; Rizzo, M. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2019, 11, 2580. https://doi.org/10.3390/nu11112580

AMA Style

Castellino G, Nikolic D, Magán-Fernández A, Malfa GA, Chianetta R, Patti AM, Amato A, Montalto G, Toth PP, Banach M, Cicero AFG, Rizzo M. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2019; 11(11):2580. https://doi.org/10.3390/nu11112580

Chicago/Turabian Style

Castellino, Giuseppa; Nikolic, Dragana; Magán-Fernández, Antonio; Malfa, Giuseppe A.; Chianetta, Roberta; Patti, Angelo M.; Amato, Antonella; Montalto, Giuseppe; Toth, Peter P.; Banach, Maciej; Cicero, Arrigo F.G.; Rizzo, Manfredi. 2019. "Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study" Nutrients 11, no. 11: 2580. https://doi.org/10.3390/nu11112580

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop